Peiqi Zhao

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 6

Top Topics

Combination Therapy

Papillary Thyroid

Top Venues

International journal of nanomedicine

Hematological oncology

Journal of nanobiotechnology

ACS applied materials & interfaces

This page only lists publications with an associated author ORCID identifier.

Publications

Peiqi Zhao, Yuanlin Xu, Wei Ji, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Huilai Zhang
Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy. International journal of nanomedicine 17 (2022)
Yingying Zhang, Xin Xue, Mingxi Fang, Gaoju Pang, Yujuan Xing, Xinyu Zhang, Lianyue Li, Qu Chen, Yuxin Wang, Jin Chang, Peiqi Zhao, Han-Jie Wang
Upconversion Optogenetic Engineered Bacteria System for Time-Resolved Imaging Diagnosis and Light-Controlled Cancer Therapy. ACS applied materials & interfaces 14 (41) (2022)
Peiqi Zhao, Yuanlin Xu, Wei Ji, Shiyong Zhou, Lanfang Li, Lihua Qiu, Zhengzi Qian, Xianhuo Wang, Huilai Zhang
Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer. Journal of nanobiotechnology 19 (1) (2021)
Peiqi Zhao, Lihua Qiu, Shiyong Zhou, Lanfang Li, Zhengzi Qian, Huilai Zhang
Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy. International journal of nanomedicine 16 (2021)
Peiqi Zhao, Lei Zhu, Zheng Song, Xianhuo Wang, Wenchao Ma, Xiang Zhu, Lihua Qiu, Lanfang Li, Shiyong Zhou, Zhengzi Qian, Wengui Xu, Huilai Zhang
Combination of baseline total metabolic tumor volume measured on FDG-PET/CT and β2-microglobulin have a robust predictive value in patients with primary breast lymphoma. Hematological oncology 38 (4) (2020)
Peiqi Zhao, Lanfang Li, Shiyong Zhou, Lihua Qiu, Zhengzi Qian, Xianming Liu, Bin Meng, Huilai Zhang
CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Hematological oncology 37 (4) (2019)